Could upfront temozolomide chemotherapy postpone the need for radiotherapy in young patients with high-risk low-grade gliomas?

NCT02209428 was initiated in 2014, as a prospective, one-arm, open-label study in a single tertiary specialized center (Glioma Surgery Division, Neurological Surgery Department of Huashan Hospital, Fudan University) in Shanghai, China. Patients were followed up by magnetic resonance imaging for tumo...

Full description

Saved in:
Bibliographic Details
Published in:Chinese medical journal 2021-03, Vol.134 (11), p.1356-1358
Main Authors: Li, Ze-Yang, Yuan, Shi-Wen, Song, Yan-Yan, Hameed, N.U. Farrukh, Chen, Hong, Zhuang, Dong-Xiao, Lu, Jun-Feng, Gong, Fang-Yuan, Aibaidula, Abudumijit, Shi, Zhi-Feng, Wu, Shuai, Guo, Qi-Hao, Wu, Jin-Song
Format: Article
Language:English
Subjects:
Antineoplastic Agents, Alkylating - therapeutic use
Aphasia
Brain cancer
Brain Neoplasms - drug therapy
Chemotherapy
Clinical Observations
Glioma
Glioma - drug therapy
Glioma - radiotherapy
Humans
Multilingualism
Neuropsychology
Patients
Radiation therapy
Surgery
Temozolomide - therapeutic use
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:NCT02209428 was initiated in 2014, as a prospective, one-arm, open-label study in a single tertiary specialized center (Glioma Surgery Division, Neurological Surgery Department of Huashan Hospital, Fudan University) in Shanghai, China. Patients were followed up by magnetic resonance imaging for tumor volume and neuropsychological evaluation. The primary endpoint is objective response rate (ORR), and objective response includes complete response (CR), partial response (PR), and minor response (MR). [4] Secondary endpoints include: (1) intensity of response (IOR), defined as the ratio of maximum volume reduction to residual volume after operation; (2) duration of response (DOR) is used instead of PFS; (3) malignant progression-free survival (MPFS), cognitive function results, and the safety of chemotherapy.
ISSN:0366-6999
2542-5641
DOI:10.1097/CM9.0000000000001434